Stoke Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $184.4M | $36.6M | $8.8M | $12.4M |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | $137.9M | $89.1M | $82.2M | $77.8M |
| SG&A Expense | $67.1M | $48.8M | $41.3M | $38.9M |
| Operating Income | $-20.6M | $-101.4M | $-114.8M | $-104.4M |
| Operating Margin | -11.2% | -277.3% | -1,307.2% | -841.2% |
| Interest Expense | $9.0K | $26.0K | $49.0K | — |
| Pretax Income | — | — | — | — |
| Income Tax Expense | $0 | — | — | — |
| Net Income | $-6.9M | $-89.0M | $-104.7M | $-101.1M |
| Net Margin | -3.7% | -243.4% | -1,192.5% | -814.7% |
| EPS (Basic) | $-0.12 | $-1.65 | $-2.38 | $-2.60 |
| EPS (Diluted) | $-0.12 | $-1.65 | $-2.38 | $-2.60 |
| Shares Outstanding (Basic) | 59.2M | 54.0M | 44.0M | 38.9M |
| Shares Outstanding (Diluted) | 59.2M | 54.0M | 44.0M | 38.9M |
| Dividends Per Share | — | — | — | — |